Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Core Viewpoint - Hims & Hers Health has reached an agreement with Novo Nordisk to sell its popular GLP-1 weight loss drugs, leading to a significant increase in its stock price, raising questions about the timing for potential investors [1]. Group 1: Company Relationship - Hims & Hers and Novo Nordisk have experienced a tumultuous relationship, with a previous partnership that ended due to Hims allegedly not fulfilling its obligations by selling compounded versions of Novo's drugs illegally [2]. - Hims had previously argued it had the legal right to sell personalized versions of the drugs during a shortage, but the FDA declared the drug was no longer in shortage in February 2025, complicating the situation [3]. Group 2: Legal and Business Developments - The new agreement allows Hims to offer Ozempic injections and Wegovy pills, while still providing some personalized compounded semaglutide drugs when medically necessary, although it will not advertise this option [4]. - The lawsuit initiated by Novo Nordisk against Hims will be dropped as part of this new agreement, removing a significant overhang for Hims [5]. Group 3: Market Implications - The agreement with Novo Nordisk signifies a return to collaboration, highlighting the reach of Hims' platform and is expected to drive growth, albeit at a lower gross margin [5].